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The essential fatty acid eicosapentaenoic acid (EPA) present in fish oils displays beneficial 
effects in a range of human disorders associated with inflammation including cardiovascular 
disease. Resolvin E1 (RvE1), a new bioactive oxygenated product of EPA, was identified in 
human plasma and prepared by total organic synthesis. Results of bioaction and physical 
matching studies indicate that the complete structure of RvE1 is 5S,12R,18R-trihydroxy-
6Z,8E,10E,14Z,16E-EPA. At nanomolar levels, RvE1 dramatically reduced dermal 
inflammation, peritonitis, dendritic cell (DC) migration, and interleukin (IL) 12 production. We 
screened receptors and identified one, denoted earlier as ChemR23, that mediates RvE1 signal 
to attenuate nuclear factor–
 
 
 
B. Specific binding of RvE1 to this receptor was confirmed using 
synthetic [
 
3
 
H]-labeled RvE1. Treatment of DCs with small interference RNA specific for 
ChemR23 sharply reduced RvE1 regulation of IL-12. These results demonstrate novel 
counterregulatory responses in inflammation initiated via RvE1 receptor activation that 
provide the first evidence for EPA-derived potent endogenous agonists of antiinflammation.
 
Clinical assessment of dietary supplementation
with omega-3 polyunsaturated fatty acids (
 
 
 
-3
PUFAs) indicate their beneficial impact in
certain human diseases, particularly those in
which inflammation is suspected as a key com-
ponent in pathogenesis (1–3). Their molecular
bases of action in reducing disease and local in-
flammation are important and of interest given
the heightened awareness that inflammation
and resolution are major mechanisms involved
in many diseases, including cardiovascular dis-
ease, arthritis, Alzheimer’s disease, asthma, and
periodontitis (4, 5). 
 
 
 
-3 PUFAs are widely
held to act via several possible mechanisms,
such as preventing conversion of arachidonate
to proinflammatory eicosanoids or serving as
an alternative substrate producing less potent
products (1). Of interest, fish leukocytes rich
in 
 
 
 
-3 PUFA generate mediators from eicosa-
pentaenoic acid (EPA) that play signaling roles
(6). However, the pathophysiological role of
enzymatic oxygenated compounds derived from
EPA remains of interest in humans.
Recently, we uncovered a novel family
of aspirin-triggered bioactive lipids biosynthe-
sized during the spontaneous resolution phase
of acute inflammation in vivo, coined the re-
solvins (resolution-phase interaction products),
which are potent autacoids that now may
provide molecular means that underlie 
 
 
 
-3
PUFA’s protective actions (7, 8). At local sites,
aspirin treatment enables EPA conversion to
the novel 18R series of oxygenated products,
which carry potent counterregulatory signals.
One of the main bioactive compounds of this
18R series, namely 5,12,18R-trihydroxy-EPA
(termed resolvin E1 [RvE1]) can arise via cell–
cell interactions in murine inflammatory exu-
dates, also exemplified with human vascular
endothelial cells carrying aspirin-acetylated cy-
clooxygenase (COX)-2 and leukocytes pos-
sessing lipoxygenase (LO) activity (7). Because
the GISSI paper reported a beneficial impact of
 
 
 
-3 PUFA treated in 
 
 
 
11,000 cardiovascular
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patients also taking aspirin (2), our results suggest that the
novel antiinflammatory action of EPA-derived RvE1 may,
in part, be responsible for the beneficial impact of EPA in
cardiovascular diseases.
Here, the novel lipid mediator RvE1 was identified in
humans and its complete stereochemical structure was estab-
lished as 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-EPA.
RvE1 radiolabel was prepared and shown to interact with a
G-protein–coupled receptor (GPCR) ChemR23 that medi-
ates its potent protective and antiinflammatory actions.
 
RESULTS
RvE1 generation in vivo
 
Originally RvE1 was found in vivo during resolution phase
of inflammation in exudates from murine dorsal pouches
treated with aspirin and EPA, and was generated during co-
incubation of human endothelial cells and neutrophils (7).
RvE1 was monitored using liquid chromatography-tandem
mass spectrometry (LC-MS/MS) in healthy human volun-
teers given EPA and aspirin (Fig. 1, a and b). The plasma
values ranged from 0.1 to 0.4 ng/ml for six donors. The for-
mation of RvE1 is consistent with the scheme that endothe-
lial cells expressing COX-2 treated with aspirin transform
vascular EPA to produce and release 18R-HEPE as we re-
ported earlier (7). When human leukocytes and endothelial
cells interact within the vasculature, 18R-HEPE is rapidly
converted to RvE1 via transcellular biosynthesis (Fig. 1 c).
 
Assignment of the complete stereochemistry of RvE1
 
Although the basic structure of RvE1 and actions were ini-
tially reported (i.e., 5,12,18R-trihydroxy-EPA; reference 7),
its complete stereochemical assignment remained to be es-
tablished. To assign the complete stereochemistry of RvE1
and establish its biological activities, biogenic RvE1 was pre-
pared (7) and matched with synthetic RvE1 (5S,12R,18R-
trihydroxy-6Z,8E,10E,14Z,16E-EPA), having complete ste-
reochemistry that was prepared by total organic synthesis
from isomerically pure precursors (Fig. 2 a). Several geomet-
ric isomers were prepared by organic synthesis that carried
different double bond geometries in native RvE1, namely
5S,12R,18R-6E,10E,14E,16E-triHEPE and 5S,12R,18R-
6E,8Z,10E,14Z,16E-triHEPE, to establish their chromato-
graphic and physical properties (Table S1, available at http://
www.jem.org/cgi/content/full/jem.20042031/DC1). Be-
cause RvE1 is produced in subnanogram amounts in vivo,
to assign its complete stereochemistry it was necessary to
prepare both synthetic and biogenic materials for matching
of their physical properties using UV spectroscopy, LC-MS/
MS, gas chromatography mass spectrometry, and impor-
tantly compared biological activities. Of the isomers pre-
pared and studied, the matching synthetic compound eluted
beneath a single peak in HPLC with UV absorbance maxima
271 nm and 234 nm, indicative of conjugated triene and di-
ene in the molecule. MS/MS fragmentation ions were es-
sentially identical with the biogenic material, namely a par-
ent ion at m/z 349 
 
 
 
 [M-H]
 
 
 
 and diagnostic product ions at
m/z 
 
 
 
291 and 195 (Fig. 2 b). Results of physical matching
studies are summarized in Table S1. Administration of as lit-
tle as 100 ng/mouse of synthetic RvE1 stopped leukocyte
infiltration into inflammatory loci by 50
 
 
 
70% in the TNF-
 
 
 
–induced dorsal air pouch, which proved to be as potent as
the biogenic material (Fig. 2 c). For comparison in this
Figure 1. Lipidomic analysis of RvE1 in human plasma. (a) Representa-
tive MS/MS selected ion chromatogram at m/z 291 and (b) MS3 selected ion 
chromatogram at m/z 229. (c) Scheme of RvE1 generation from EPA. Human 
endothelial cells expressing COX-2 treated with aspirin transform EPA by ab-
stracting hydrogen at C16 to give R insertion of molecular oxygen to yield 
18R-H(p)EPE. Alternatively, cytochrome P450 monooxygenase can convert 
EPA to 18R-HEPE (reference 28). They are further converted via sequential ac-
tions of a leukocyte 5-LO–like reaction, which leads to formation of RvE1. 
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model, local administration of dexamethasone (10 
 
 
 
g/
mouse) gives 60% inhibition (Fig. 2 c) and aspirin (1.0 mg/
mouse) gives 70% inhibition of leukocyte recruitment (9),
indicating that RvE1 at nanomolar level is as potent as
higher doses of dexamethasone or aspirin in stopping leuko-
cyte infiltration. Also indomethacin (100 ng/mouse) gave
25% inhibition and RvE1 (100 ng/mouse) gave 50
 
 
 
60% in-
hibition of leukocyte recruitment in zymosan-induced peri-
tonitis (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20042031/DC1). The 18
 
S
 
 isomer gave es-
sentially equivalent activity as native RvE1 containing 18R,
whereas the 6-trans,14-trans isomer showed reduced po-
tency (
 
 
 
70%) for reducing leukocyte infiltration in zymo-
san-induced peritonitis (unpublished data). Based on match-
ing of physical and biological properties, the 18R series
RvE1, a potent antiinflammatory lipid mediator, was
assigned the complete structure 5S,12R,18R-trihydroxy-
6Z,8E,10E,14Z,16E-EPA.
 
Identification of receptor candidate
 
The murine air pouch is widely used to assess dermal inflam-
mation (Fig. 2 c); it is characterized by a cavity and a lining
composed of both fibroblast-like and macrophage-like cells
(10). Intrapouch application of TNF-
 
 
 
 evokes leukocyte in-
filtration by stimulating local release of chemokines and
chemoattractants that are often produced by fibroblasts and
phagocytes via regulation of NF-
 
 
 
B transcription factors
(11). Systemic administration of RvE1 dramatically attenu-
ated leukocyte recruitment (Fig. 2 c), suggesting the receptor
target for RvE1 was expressed in those cells, which counter-
regulate TNF-
 
 
 
–induced NF-
 
 
 
B activation. RvE1 and li-
poxin (LX) A
 
4
 
 have different structures and are formed via
different biosynthetic pathways and precursors (EPA vs.
arachidonate), yet they appear to share redundant beneficial
properties that dampen excessive leukocyte recruitment (12);
therefore, we reasoned that RvE1 receptors might share sim-
ilar structural features to LO-derived eicosanoid receptors
such as LXA
 
4
 
 receptor (ALX) and leukotriene B
 
4
 
 receptor
(13).
Fig. 3 a shows a branch of the phylogenetic tree of hu-
man ALX with closely related GPCRs. Expression plasmids
of each GPCR were introduced into HEK293 cells, and the
ability of RvE1 to inhibit TNF-
 
 
 
–stimulated NF-
 
 
 
B activa-
tion was monitored by cotransfection with NF-
 
 
 
B response
element–luciferase reporter plasmid. This permitted an unbi-
ased analysis of the activation of the relevant postligand re-
ceptor “stop” signaling for down-regulation of NF-
 
 
 
B acti-
vation as, for example, demonstrated with ALX-transfected
cells and its ligands (14). Among those screened (Fig. 3 b),
the orphan receptor denoted earlier as ChemR23 (15) was
specifically activated by RvE1 and, at 10 nM, inhibited NF-
 
 
 
B activation (Fig. 3 b). ChemR23 shares 36.4% identity
with ALX in deduced amino acid sequences and, of note, it
contains a highly conserved domain within its second intra-
cellular loop with 75% identity and within the seventh trans-
membrane region with 69.5% identity (Fig. 3 c).
Figure 2. Properties of RvE1. (a) Total organic synthesis of RvE1. Pre-
cursors 1–3 were prepared in isomerically pure form from starting materi-
als with known stereochemistry and coupled sequentially to form acety-
lenic intermediate compound 4, which was selectively hydrogenated to 
form isomerically pure RvE1. (b) MS/MS spectrum of synthetic RvE1. (c) 
Inhibition of leukocyte trafficking in murine dorsal air pouch. 18R-HEPE 
and RvE1 (biogenic and synthetic) are at 100 ng/mouse, and dexametha-
sone is at 10  g/mouse. Values represent mean   SEM from five different 
mice. *, P   0.05 (vs. vehicle control). 
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RvE1 gave concentration-dependent inhibition of TNF-
 
 
 
–induced NF-
 
 
 
B activation with an EC
 
50
 
 of 
 
 
 
1.0 nM in
ChemR23-transfected cells, but not in mock-transfected cells
(Fig. 3 d). In this system, 1 mM aspirin, a known inhibitor of
NF-
 
 
 
B at high concentrations (namely millimolar range;
reference 16), gave nonreceptor-dependent inhibition of
26.2 
 
 
 
 4.9% for the transfected cells. Neither EPA nor 18R-
HEPE at 100 nM, both metabolic precursors of RvE1, inhib-
ited NF-
 
 
 
B in ChemR23-transfected cells (Fig. 3 e). The
double bond isomer of RvE1, 6-trans,14-trans-RvE1, at 100
nM showed reduced potency for NF-
 
 
 
B inhibition that was
essentially the same magnitude reduction in vivo. We also
examined functional interactions between ChemR23 and
G-proteins using ligand-dependent binding of [
 
35
 
S]-GTP
 
 
 
S,
a hydrolysis resistant GTP analogue. Specific [
 
35
 
S]-GTP
 
 
 
S
binding in isolated membranes obtained from cells expressing
ChemR23 increased selectively with RvE1 in a concentra-
tion-dependent manner (Fig. 3 f). These results indicate that
RvE1 transmits signal as a selective agonist via ChemR23 and
counterregulates TNF-
 
 
 
–stimulated NF-
 
 
 
B activation.
 
Radioligand binding
 
To determine RvE1 binding to ChemR23, tritium-labeled
RvE1 was prepared by catalytic hydrogenation from syn-
Figure 3. RvE1 receptor. (a) Phylogenetic tree representing amino acid 
sequence similarities between the human LXA4 receptor (ALX) and related 
GPCRs. (b) Functional screening for RvE1 receptors. HEK293 cells cotrans-
fected with pNF- B-luciferase and pcDNA3-GPCRs were exposed to RvE1 
(10 nM) and TNF- . (c) Amino acid sequence alignment of human 
ChemR23 with ALX. Asterisks indicate conserved amino acids. Putative 
transmembrane domains are lined and labeled I–VII. (d) RvE1 inhibits lu-
ciferase activity in a concentration-dependent manner on cells trans-
fected with pcDNA3-ChemR23 (closed circles) but not pcDNA3 (open cir-
cles). (e) Ligand specificity for ChemR23. Cells transfected with pcDNA3-
ChemR23 were exposed to 100 nM of each compound. Results are ex-
pressed as percent inhibition of luciferase activity and represent the
mean   SEM from n   3 (b) or n   4 (d and e); *, P   0.05. (f) Actions
of RvE1 (closed circles), RvE1 derivative (6,14-diacetylenic-RvE1; open 
rectangle), and 18R-HEPE (closed diamonds) on [35S]-GTP- S binding to 
membrane expressing ChemR23. Results are expressed as a percentage of 
vehicle control with the mean   SEM (n   3). *, P   0.05. 
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thetic diacetylenic RvE1 (Fig. 2 a, compound labeled 4). In-
tegrity of the synthetic [
 
3
 
H]-RvE1 was confirmed by HPLC;
radioactive compound coeluted with synthetic RvE1 be-
neath a single peak in HPLC. Its characteristic UV absor-
bance maxima at 271 nm and 234 nm were indicative of the
conjugated triene and diene in RvE1 structure (Fig. 4 a).
Analysis of [
 
3
 
H]-labeled RvE1-specific binding and Scat-
chard transformation is shown in Fig. 4 b. [
 
3
 
H]RvE1 bound
to an apparent single site on ChemR23 transfectants with
high affinity (Kd 
 
  
 
11.3 
 
 
 
 5.4 nM, Bmax 
 
  
 
4,200 
 
 
 
 1,050
binding sites per cell). RvE1 biosynthesis precursors, EPA
and 18R-HEPE, did not compete for specific [
 
3
 
H]RvE1
binding (Fig. 4 c). We also tested the synthetic peptide frag-
ment (YHSFFFPGQFAFS) derived from chemerin that was
reported recently (while the present studies were in progress)
to be a peptide ligand for this same receptor (17). Chemerin
peptide at 10 
 
 
 
M competed for specific [
 
3
 
H]RvE1 binding
by 
 
 
 
70%, suggesting that lipid ligand RvE1 and peptide
ligand chemerin share recognition sites on the same receptor
ChemR23.
 
Expression, regulation, and signaling properties of ChemR23
 
Tissue distribution of human ChemR23 was determined
with dot blots containing mRNAs from human tissues that
showed expression of ChemR23 in several tissues, such
as cardiovascular system, brain, kidney, gastrointestinal tis-
sues, and myeloid tissues (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20042031/DC1). Also,
a murine receptor counterpart was found in developing bone
using in situ hybridization (18). Among the human peripheral
blood leukocytes, ChemR23 was abundantly expressed in
monocytes, with lower amounts in neutrophils and T lym-
phocytes (Fig. 5 a), findings consistent with the observation
that this receptor is expressed in APCs such as macrophages
Figure 4. Labeled RvE1 and specific binding. (a) Elution profile of the 
[3H]-labeled RvE1 on reverse phase HPLC. Tracing was recorded at 270 nm 
absorbance and chromatographic peak at the same retention time as 
standard RvE1 is indicated by the asterisk. The inset shows the online UV 
spectrum of the product. (b) [3H]-RvE1–specific binding to ChemR23. Hu-
man ChemR23–transfected (closed circles) or mock-transfected (open in-
verted triangles) CHO cells (106 cells) were incubated with indicated con-
centrations of [3H]-RvE1 in the presence or absence of 10  M of 
unlabeled RvE1. Saturation curve and Scatchard plot (inset) are represen-
tative of n   3. (c) Binding specificity. Human ChemR23-transfected CHO 
cells (106 cells) were incubated with 10 nM of [3H]-RvE1 in the presence of 
10  M of RvE1, EPA, 18R-HEPE, or chemerin peptide. Results are ex-
pressed as percent competition of [3H]-RvE1–specific binding. Results rep-
resent the mean   SEM from duplicates of n   3 5. p-values were ob-
tained by Student’s t test comparing heteroligand (i.e., EPA, 18R-HEPE, or 
chemerin) with homoligand (i.e., RvE1). *, P   0.01; #, P   0.07.OMEGA-3 ANTIINFLAMMATORY AGONIST RESOLVIN E1 | Arita et al. 718
and DCs (15, 17). Both monocyte ChemR23 and COX-2
transcripts were highly up-regulated by treatment with
inflammatory cytokines such as TNF-  and IFN- , and
ChemR23 showed delayed induction to that of COX-2 (Fig.
5 b). RvE1 increased phosphorylation of extracellular signal-
regulated kinase (ERK) mitogen-activated protein (MAP)
kinase both in peripheral blood monocytes and HEK-
ChemR23 cells, but not in mock-transfected HEK293 cells
(Fig. 5 c). In addition, treatment of HEK-ChemR23 with
pertussis toxin (PTX) abolished RvE1-dependent ERK acti-
vation and NF- B inhibition, suggesting coupling to G i/o
protein for the signal transduction (Fig. 5 d).
Because both RvE1 and chemerin peptide competed at
the same receptor, it was of interest to determine whether
there was a divergence between the activities of the two
ligands. Chemerin-derived peptide activated ChemR23 as
monitored by microphysiometry, evoking a response consis-
tent with receptor-initiated increases in extracellular acidifica-
tion rates (EARs; Fig. 5 e, red line). These results are in line
with the reported properties of this peptide ligand (17). Of
interest, the lipid RvE1 did not increase the EAR but selec-
tively blocked the peptide-evoked responses (Fig. 5 e, blue
line). Consistently, the extent of G-protein activation evoked
by chemerin peptide was three times as much as RvE1 (Fig. 5
f). Alternately, RvE1 was an order of magnitude more po-
tent than chemerin peptide for inhibiting NF- B activation
(Fig. 5 g). These results suggest that RvE1 interacts with
ChemR23 and transmits signals via this receptor in a fashion
different than that of the chemerin-derived peptide.
RvE1-ChemR23 interaction blocks splenic DC response 
to pathogen
Given expression of ChemR23 in APCs and because APC
function is influenced by dietary  -3 PUFA supplementation
Figure 5. Receptor expression. (a) RT-PCR analysis of human periph-
eral blood leukocytes and glioma (DBTRG-05MG), monocytic (THP-1), lung 
epithelial (A549), hepatoma (HepG2), embryonic kidney (HEK293) cell lines, 
and brain and liver. (b) RT-PCR analysis of human peripheral blood mono-
cytes exposed to either buffer alone, 10 ng/ml TNF- , or 25 ng/ml IFN-  
for 6 h (gray bars) and 24 h (black bars). Expression levels were quantified 
by a National Institutes of Health image, normalized by GAPDH levels, and 
expressed as fold increase over vehicle-treated cells. (c) MAP kinase acti-
vation in human peripheral blood monocytic cells were exposed to RvE1 
for 5 or 15 min and HEK-ChemR23 cells were treated with 100 nM RvE1 
(E) or vehicle (V). (d) Pertussis toxin (PTX) blocks RvE1-induced ERK activa-
tion and NF- B inhibition in HEK-ChemR23 cells. (e) EAR with HEK-
ChemR23 cells exposed to vehicle (red line), 100 nM RvE1 (blue line), 10 
 M chemerin peptide, or 10  M ATP using Cytosensor microphysiometer. 
These responses were observed from three separate experiments. (f) Ac-
tions of RvE1 (red) and chemerin peptide (black) on [35S]-GTP- S binding 
to HEK293 cell membranes expressing human ChemR23. (g) Inhibition of 
TNF-  induced NF- B luciferase activities by RvE1 (red) and chemerin 
peptide (black) on HEK293 cells expressing human ChemR23.JEM VOL. 201, March 7, 2005 719
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(19), next we examined the activity of RvE1 on APC func-
tion using a microbial pathogen model. Injection of pathogen
extract derived from Toxoplasma gondii soluble tachyzoite an-
tigen (STAg) causes activation of splenic DCs to mobilize to
T cell–enriched areas where they produce high amounts of
IL-12 (20). Addition of increasing concentrations of RvE1 to
isolated mouse splenic CD11c  DCs markedly inhibited IL-
12p40 production by STAg within the nanomolar range (Fig.
6 a). Next, we performed small interference RNA (siRNA)
experiments to reduce ChemR23 in splenic DCs. Mouse
receptor (18), which shares 80.3% identity with human
ChemR23, was also present in splenic DCs. RvE1’s action in
regulating IL-12 production from DCs was eliminated by
treatment with a siRNA specific for the mouse ChemR23
(Fig. 6 b). We confirmed that this siRNA treatment dramati-
cally reduced ChemR23 mRNA expression in DCs (Fig. 6 b,
inset) and cell surface expression of recombinant ChemR23
in HEK293 cells (Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20042031/DC1). These results confer
that RvE1’s antiinflammatory action is mediated via Chem-
R23. In vivo treatment with RvE1 also blocked IL-12 pro-
duction (Fig. 6 c) as well as DC migration into T cell areas of
the spleen (Fig. 6, d–g).
DISCUSSION
Acute inflammation is a protective host response to chal-
lenge and/or tissue injury that can, if unopposed, lead to loss
of tissue structure and function. In many chronic disorders,
prolonged and unresolved inflammation is held to contribute
to pathogenesis (4). The resolution of inflammation is an ac-
tive process controlled in part by endogenous chemical me-
diators that counterregulate proinflammatory gene expres-
sion and cell trafficking as well as stimulate inflammatory cell
clearance (11, 21). Also, our finding that cytokines up-regu-
lated ChemR23 as well as COX-2 in monocytes suggests
that, in scenarios where COX-2 is induced during inflam-
mation, monocytes as well as endothelial cells treated with
aspirin can also generate and respond to RvE1. Hence,
RvE1 may serve an autocrine and/or paracrine signal during
resolution to terminate further NF- B activation and cyto-
kine production in a temporal and spatially regulated fashion.
RvE1 is generated in healthy human volunteers given EPA
and aspirin (Fig. 1), results that are consistent with the no-
tion that COX-2 is also constitutively expressed within the
vasculature of healthy subjects (22, 23). Thus, the present re-
sults support the notion that aspirin, in addition to its well-
appreciated action to inhibit prostanoid formation, can exert
Figure 6. RvE1 regulates DCs. (a) RvE1 inhibits DC IL-12 production in 
vitro stimulated by pathogen extract (STAg). CD11c  DCs incubated with 
vehicle (open circles) or RvE1 (closed circles) before STAg or no STAg (open 
squares). (b) Reduction of ChemR23 expression by siRNA eliminates RvE1 
signaling. Expression of ChemR23 and GAPDH mRNA from DCs treated 
with either scramble or ChemR23-specific siRNAs (inset). Spleen cells 
transfected with siRNAs were treated with vehicle (ethanol, 0.1% vol/vol) 
or RvE1 (1.0  g/ml). 8 h later, cells were stimulated with 10  g/ml STAg 
and IL-12p40 was measured. Bars represent mean   SD (n   3), *, P   
0.05 (control vs. specific siRNA). (c) RvE1 blocks IL-12 production in vivo. 
Mice administered with either 100 ng RvE1 or vehicle were challenged in-
traperitoneally with PBS or STAg, and IL-12p40 secretion from splenic 
CD11c  DCs was measured. (d–g) RvE1 blocks trafficking of CD11c  DCs 
in spleen with pathogen extract challenge. Spleens from mice given 10  g 
RvE1 or vehicle were stained for CD11c. (d) PBS plus vehicle (e) STAg plus 
vehicle (f) PBS plus RvE1 (g) STAg plus RvE1. Arrows indicate CD11c posi-
tive DCs accumulated in T cell–enriched area.OMEGA-3 ANTIINFLAMMATORY AGONIST RESOLVIN E1 | Arita et al. 720
its beneficial actions, in part, via EPA catabolic synthesis of
18R series RvE1 that in turn interacts with receptors such as
ChemR23 to dampen further proinflammatory processes.
Endogenous chemically redundant antiinflammatory
lipid autacoids act with high affinities (nM range) and stereo-
selectivity on structurally related receptors, as does aspirin-
triggered LXA4 generated from arachidonic acid (24) to en-
hance resolution by “stopping” PMN recruitment and IL-12
production from APCs (20). RvE1 also blocked PMN
transendothelial migration in vitro (7) and inhibited migra-
tion and IL-12 production from APCs (Fig. 6). It is of note
that this bioactive lipid mediator RvE1 and new peptide
ligand from chemerin (17) can each serve as endogenous
ligands at the same GPCR but transmit different ligand-
dependent signals (Fig. 5). It appears that the receptor activa-
tion evoked by ligand binding and their intracellular signal
transductions are different for peptide versus lipid ligands of
ChemR23 and, hence, they can dictate different functional
responses in vivo. Chemerin was described recently as a
novel chemoattractant peptide that selectively promotes che-
motaxis of APCs such as immature DCs and macrophages in
vitro (17). Alternately, here we showed that RvE1 blocked
DC migration and IL-12 production in response to patho-
gen in vivo (Fig. 6). Temporal and spatial coordination of
the recruitment and activation of APCs are important in in-
flammation and host defense, and a GPCR ChemR23 selec-
tively expressed on APCs seems to play a key role by inter-
acting with either endogenous lipid (RvE1) or peptide
(chemerin) ligands in regulating migration and activation of
this particular cell type in vivo. This appears to be a similar
scenario to LXA4 and its receptor ALX expressed on PMNs,
which also interacts with both specific lipid and peptide
ligands to transmit ligand-dependent signals (reference 25
and for a recent review see reference 26). Because Chem-
R23 and ALX share overall structural similarities and strongly
conserved domains, the “dual ligand” as well as antiinflam-
matory and proresolving properties might be conserved in
these structurally related GPCRs.
Together, our findings offer an endogenous agonist–
driven molecular mechanism that can underlie some of the
beneficial actions of  -3 EPA observed in many clinical situ-
ations (1–3) as well as identify novel components in endoge-
nous antiinflammation/resolution, namely RvE1 and its re-
ceptor that are of interest as new checkpoint regulators (21)
that may be involved in the pathogenesis of a wide range of
human diseases.
MATERIALS AND METHODS
LC-MS/MS analysis of RvE1.  Human plasma samples were collected
at 4 h after oral administration of fish oil supplement (fish oil concentrate;
Walgreens) containing 1 g EPA and 0.7 g DHA followed by 160 mg aspirin
at 3 h in six healthy volunteers. Plasma samples were extracted by C18 solid
phase extraction with d4-LTB4 (Cascade Biologics, Inc.) as internal standard
for LC-MS/MS analysis (7) using a Finnigan LCQ liquid chromatography
ion trap tandem mass spectrometer equipped with a LUNA C18-2 (100  
2 mm   5  m) column and UV diode array detector using mobile phase
(methanol:water:acetate at 65:35:0.01) with a 0.2 ml/min flow rate.
Murine dorsal air pouch model.  Dorsal air pouches were raised on
male FvB mice (6–8 wk) by injecting 3 ml of sterile air subcutaneously on
days 0 and 3. On day 6, 100 ng/mouse of compounds were injected into
the tail vein. Inflammation in the air pouch was induced by intrapouch in-
jection of mouse recombinant TNF-  (100 ng/pouch), pouch lavages were
collected at 4 h, and cells were enumerated.
Zymosan-induced peritonitis.  For peritonitis, 100 ng/mouse of RvE1
or related structures was injected into tail vein and followed by 1 ml zymo-
san A (1 mg/ml) into the peritoneum. Peritoneal lavages were collected at
2 h and cells were enumerated.
GPCR cDNAs and phylogenetic tree.  GPCR cDNAs were cloned
by RT-PCR using specific primers designed according to the GenBank/
EMBL/DDBJ database; human FPR (P21462), ALX (P25090), FPRL2
(P25089), GPR1 (A55733), GPR32 (O75388), ChemR23 (Q99788),
CRTH2 (Q9Y5Y4), C3AR (Q16581), C5AR (P21730), BLT1 (Q15722),
and mouse ChemR23 (U79525). The phylogenetic tree was constructed
using the “All All Program” at the Computational Biochemistry Server at
ETHZ (http://cbrg.inf.ethz.ch/Server/AllAll.html).
NF- B reporter gene expression. HEK293 cells (1.0   105 cells) were
transiently transfected with 50 ng pNF- B luciferase (Stratagene), 500 ng of
either pcDNA3 or pcDNA3-GPCRs, and the internal standard pRL-TK
(Promega) using Superfect transfection reagent (QIAGEN). After 24 h, cells
were exposed to the test compounds for 30 min and stimulated with 1.0
ng/ml recombinant human TNF-  (BD Biosciences) for 5 h. Luciferase ac-
tivity was measured by the Dual-Luciferase reporter assay system (Promega).
Basal induction of luciferase activity by TNF-  was  150-fold in this sys-
tem. For PTX treatment, HEK293 cells were treated with 200 ng/ml PTX
for 24 h before stimulation.
[35S]-GTP S binding assay.  HEK293 cells stably expressing human
ChemR23 were homogenized in ice-cold TED buffer (20 mM Tris-HCl,
pH 7.5, 1 mM EDTA/5 mM MgCl2/1 mM DTT). Membrane fraction (10
 g) was incubated in 400  l of GTP-binding buffer (50 mM Hepes, pH 7.5,
100 mM NaCl/1 mM EDTA/5 mM MgCl2/1 mM DTT) containing 0.1
nM [35S]-GTP S ( 1,000 Ci/mmol; Amersham Biosciences) and 10  M
GDP for 30 min at 30 C. The bound and unbound [35S]-GTP S was sepa-
rated by rapid filtration through GF/C filters, and counted by liquid scintilla-
tion. Nonspecific binding was determined in the presence of 50  M of unla-
beled GTP S. Basal [35S]-GTP- S binding was 81.6   1.5 cpm/ g protein.
Radioligand binding.  Tritiated RvE1 (6,7,14,15-[3H]RvE1;  100 Ci/
mmol) was obtained by custom catalytic hydrogenation of synthetic 6,14-
diacetylenic RvE1 methyl ester (Fig. 2 a, compound 4) that was supplied to
and performed at American Radiolabeled Chemicals, and the 3H-labeled
RvE1 was saponified and isolated by HPLC. [3H]-RvE1–specific binding was
performed with CHO cells (American Type Culture Collection) transfected
with human recombinant ChemR23. Cells were suspended in Dulbecco’s
phosphate buffered saline with CaCl2 and MgCl2 (DPBS2 ). For saturation
binding, aliquots (106 cells) were incubated with increasing concentrations of
[3H]-RvE1 in the presence or absence of unlabeled homoligand (10  M) for
1 h at 14 C. To determine ligand specificity by competition binding, aliquots
(106 cells) were incubated with 10 nM of [3H]-RvE1 in the presence of vari-
ous competitors (10  M) for 1 h at 14 C. Chemerin COOH-terminal bioac-
tive peptide (YHSFFFPGQFAFS) was synthesized by SynPep Co. as de-
scribed previously (17). The bound and unbound radioligands were separated
by filtration through Whatman GF/C glass microfiber filters (Fisher Scien-
tific) and radioactivity was determined. Scatchard plot was obtained and Kd
and Bmax values were calculated using Prism (Graphpad Software, Inc.).
Dot blot hybridization and RT-PCR. Hybridization to MTE array
(CLONTECH Laboratories, Inc.) was performed using 1.1 kb.p. fragment
encoding open reading frame of ChemR23 following the manufacturer’sJEM VOL. 201, March 7, 2005 721
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protocol. Primers used in amplifications were as follows: human ChemR23,
5 -ATGAGAATGGAGGATGAAGA-3  and 5 -TCAAAGCATGCCG-
GTCTCC-3 ; mouse ChemR23, 5 -ATGGAGTACGACGCTTACAA-
3  and 5 -TCAGAGGGTACTGGTCTCCTTCT-3 ; COX-2, 5 -GCT-
GACTATGGCTACAAAAGCTGG-3  and 5 -ATGCTCAGGGACT-
TGAGGAGGGTA-3 ; and GAPDH, 5 -GACCACAGTCCATGACAT-
CACT-3  and 5 -TCCACCACCCTGTTGCTGTAG-3 . Amplified products
were confirmed by direct sequencing.
MAP kinase activation.  MAP kinase activation in monocytes and
HEK293 cells after treatment with 100 nM of each compound was deter-
mined. After incubations, cells were lysed in cold lysis buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 1.0% NP-40, 0.5% sodium
deoxycolate, 10 mM NaF, 10 mM sodium pyrophosphate) containing pro-
tease inhibitor cocktail (Sigma-Aldrich). 40  g of protein was separated on
SDS-PAGE and immunoblot was performed using anti–phospho-p44/42
MAP kinase (Cell Signaling Technology) and anti-ERK (Santa Cruz Bio-
technology, Inc.) antibodies. For PTX treatment, HEK-ChemR23 cells
were incubated with or without 200 ng/ml PTX for 24 h at 37 C and ERK
activation was monitored by addition of 100 nM RvE1 for 5 min.
Ligand-activated EAR.  Changes in HEK293 EARs were evaluated by
use of a Cytosensor microphysiometer (Molecular Devices) as described
previously (27). Cells were seeded into 12-mm Transwell inserts (3.0  m
pore size) at 5   104 cells and cultured for 2 d. Capsules were placed in sen-
sor chambers and equilibrated for 30 min in MD-RPMI 1640 (1 mM phos-
phate). EARs were monitored at 30-s potentiometric rate measurements
( V/s; pump off cycle) after an 80-s pump cycle with a 10-s delay (120 s to-
tal cycle time). Cells were perfused with the indicated agonists for 30-s be-
fore the first rate measurements.
Activation of spleen DCs with pathogen extract (STAg).  Experi-
ments were performed essentially as described previously (20). STAg was
prepared from sonicated T. gondii (RH strain) tachyzoites. For isolated DC
experiments, 70–85% CD11c  DCs were isolated from spleen. CD11c  DC
suspensions (106 cells/ml) were spread into 96-well plates and incubated for
24 h with RvE1 before the addition of 5  g/ml STAg. After overnight cul-
ture, supernatants were collected and IL-12p40 was measured with a sand-
wich ELISA. For in vivo treatments, C57BL/6 mice (n   3 per group) were
injected intravenously with 100 ng RvE1. After 18 h, the animals were chal-
lenged intraperitoneally with PBS (0.2 ml/mouse) and 5  g/ml STAg and
killed after an additional 6 h. CD11c  DCs were isolated from spleen and
IL12-p40 secretion was measured at 24 h. For DC migration, splenic frozen
section from mice treated as described before (but given 10  g of RvE1 or
vehicle) were stained for CD11c and counterstained with hematoxylin.
RNA interference.  Synthetic siRNA for mouse ChemR23, 5 -AAC-
ACUGUGUGGUUUGUCAACdTdT-3 , and nonspecific control IX
siRNA, 5 -AUUGUAUGCGAUCGCAGACUU-3 , were obtained from
Dharmacon Research. Spleen cells (106 cells/ml) were transfected using
Chariot (Active Motif) following the manufacturer’s instructions. In brief,
siRNA was mixed with Chariot transfection reagent and incubated at room
temperature for 30 min. Spleen cells were plated in serum-free RPMI 1640
medium and 200 ng siRNA/Chariot solution was added and incubated for
2 h at 37 C, followed by the addition of 10% FCS RPMI 1640 to the cul-
tures. To assure effective inhibition of gene expression, cells were further
incubated for 30 h at 37 C before STAg stimulation.
Online supplemental material.  Table S1 summarizes the chromato-
graphic, physical, and chemical properties of the biogenic RvE1, synthetic
RvE1, and its geometric isomers for both HPLC-UV-MS/MS and gas
chromatography mass spectrometry analyses. Fig. S1 demonstrates the bio-
logical property of synthetic RvE1 that inhibits leukocyte infiltration in
murine zymosan-induced peritonitis. Fig. S2 shows the human tissue distri-
bution of ChemR23 by dot blot hybridization. ChemR23 is expressed in
several tissues including the cardiovascular system, brain, kidney, gas-
trointestinal tissues, and myeloid tissues. Fig. S3 demonstrates the selectivity
of mouse ChemR23-specific siRNA using transiently transfected HEK293
cells affirming its validation for use with mouse DCs (Fig. 6 b). Studies re-
ported here were performed using protocols approved by Harvard Medical
Area Standing Committee on animals and human subjects in accordance with
the Brigham and Women’s Human Research Committee. Online supple-
mental material is available at http://www.jem.org/cgi/content/full/jem.
20042031/DC1.
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